Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial,
Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
Jamie M. Aye, Laura L. Stafman, Adele P. Williams, Evan F. Garner, Jerry E. Stewart, Joshua C. Anderson, Smitha Mruthyunjayappa, Mary G. Waldrop, Caroline D. Goolsby, Hooper R. Markert, Colin Quinn, Raoud Marayati, Elizabeth Mroczek-Musulman, Christopher D. Willey, Karina J. Yoon, Kimberly F. Whelan, Elizabeth A. Beierle
Published Sep 17, 2019 · Vol. 10, No. 53 · pp. 5534-5548
Elisabeth Baron, Shubai Liu, Yuanyuan Hua, Junzheng Yang, Pui-Wah Choi, Wing-Chung Ng, Shu-Kay Ng, Jinyan Du, Charlene C. Ng, Xiao Zhen Zhou, Kun Ping Lu, William R. Welch, Christopher P. Crum, Ross S. Berkowitz, Shu-Wing Ng
Published Sep 3, 2019 · pp. 5724-5736
Keywords: cell cycle regulation, drug sensitivity, ovarian cancer, signal transduction, combination treatment